Please select the option that best describes you:

If a patient with initially borderline resectable pancreatic cancer receives neoadjuvant CHT followed by CRT and is ultimately deemed unresectable, do you consider an RT boost?  

Would you manage this differently based on radiation dose (36/15 fx vs 50.4/28 fx)?



Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more